TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of patients requiring analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time for rescue analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h ambulatory blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Morphine intake during the first 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of treatment for giving up smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cerebral ischemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Degree of zidovudine resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scores 24 hours after ACL reconstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid consumption during the initial 24 hours
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mental health recovery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 2-hour glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: implant failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contamination risk
Endpoint domain: Adverse events/effects
Primary endpoint: Median survival from randomization
Endpoint domain: Mortality/survival
Primary endpoint: Median PFS2
Endpoint domain: Mortality/survival
Primary endpoint: Median time from randomization to a deterioration in health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Oxygen consumption (O(2)mls/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exhaled carbon dioxide (CO(2)mls/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to complete the course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearing of actinic keratoses (AKs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: drug usefulness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: joint swelling count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 2-year disease-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: psychological distress levels of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AF episode burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phrenic nerve palsies
Endpoint domain: Adverse events/effects
Primary endpoint: complete stone clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required to hit the target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in OAB symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral nerve function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported pain score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Conversion to sinus rhythm (SR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol explicit expectancies of arousal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-first HF hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: LV end-systolic volume index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: patient-surrogate congruence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: LC-specific mortality at 10 years
Endpoint domain: Mortality/survival
Primary endpoint: termination of caregiving for any reason
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Validity of VRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consistency of VRS (interobserver variability)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mucous clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Choice of palliative approach to treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Timely completion of medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half-life of total ACTZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percentage area of blebs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity on recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: functional change over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 15-epi-LXA4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IFNγ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Performance on convergent tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the POMS subscale of Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in TSH from pre‐ to post‐rTMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Biologic side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Behavioral effects
Endpoint domain: Adverse events/effects
Primary endpoint: light-induced discomfort thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of uremic solutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of contrast-induced nephropathy (CIN)
Endpoint domain: Adverse events/effects
Primary endpoint: emotional impact of the disease
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: obtaining a job offer
Endpoint domain: Life impact
Endpoint subdomain: Employment outcomes
Primary endpoint: total attributable cost of rehabilitation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean fillings score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Labor commencement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Uterine hyperstimulation cases
Endpoint domain: Adverse events/effects
Primary endpoint: decreased stool frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of incontinent episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: maximum level of mite allergen found in the house
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of sites having greater than 2 micrograms/gm of mite allergen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean value at the site with the maximum level of mite allergen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Withdrawal Assessment Tool scores ≥ 3
Endpoint domain: Adverse events/effects
Primary endpoint: BMIC (Breast Milk Iodine Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ACR Pedi 30 response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of GLP-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: survival in study
Endpoint domain: Mortality/survival
Primary endpoint: stability without relapse for 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seat belt use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression of tumor necrosis factor alpha (TNF‐α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gene expression of peroxisome proliferator‐activated receptor gamma (PPAR‐γ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gene expression of oxidized low‐density lipoprotein receptor (LDLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: decreased vasopressor dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decreased benzodiazepine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased opiate use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total drug consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days with migraine headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of erythema nodosum lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: MDD recurrence
Endpoint domain: Mortality/survival
Primary endpoint: pain during activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: revised Constant Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: active ROMsum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: BAT-Back avoidance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of consciousness recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ascites and edema improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients requiring abdominal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: EDSS deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of teaching provided by HOs
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: DASH concordance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UV-induced erythema formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: melanin index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Individual Typology Angle (ITA°)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improved self-reported food safety practices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: VAS after 5 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative recurrence-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: incidence of any grade anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: incidence of leukopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: incidence of thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: central aortic stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: brachial stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: blood flow (FBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: PSA normalization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum B12 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: holoTC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HAM-D scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: dysphagia-free survival
Endpoint domain: Mortality/survival
Primary endpoint: cognitive improvements in memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: behavioral score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VAS pain scores at rest and on cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of sufentanil
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quality of life (QALYs)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Strength (maximum voluntary contraction force)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Decrease in BAd
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Gastric emptying time (GET1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Homogeneous enhancement of liver parenchyma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak liver signal intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and efficiency for MR imaging
Endpoint domain: Adverse events/effects
Primary endpoint: Objective vestibular dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coordination and balance functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activities of daily life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: subjective symptom frequency score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial rate of alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incisor root resorption
Endpoint domain: Adverse events/effects
Primary endpoint: Serum eosinophil cationic protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ER- breast cancer risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: muscle spasms reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: muscle force improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Axial displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ticagrelor-related dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major neurodevelopmental disabilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: lumefantrine AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: depression rating scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: emotional reaction scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: social isolation scores
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Mean hematocrit increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: LDL subfraction phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Total cholesterol and HDL-cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: C3 and C4 levels normalization or elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti‐dsDNA antibody levels normalization or lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SLE Disease Activity Index (SLEDAI) score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oocyte degeneration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: cleavage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of renal impairment
Endpoint domain: Adverse events/effects
Primary endpoint: EMG activity associated with sleep bruxism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of urethral irritation symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: lasting return to work (RTW)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: cost of occupational health services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: pre-filtered P-wave duration (FPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients reaching blood pressure target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: conjunctival hyperaemia and eyelid erythema
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of parasitaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pharmacokinetics of sirukumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of uremic pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative SVT
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of postoperative SVEBs
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in neuralgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in numbness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Inter-arm difference in diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inter-arm difference in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Subjective effects of alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour hot flashes even score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: MRS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 6-minute walking test improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apgar score (1 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Bioequivalence of AUC(0-last) and Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: Repeat revascularization procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Stable angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of breech presentation during labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Frequency of caesarean section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: PFM and TrA muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported urge to binge-eat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: access failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: mean primary patency time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: LAI score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: binge eating days/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: binge episodes/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing rates with esomeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Nighttime energy expenditure (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nighttime glucose oxidation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nighttime fat oxidation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: overall mission times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: operators' performance of tasks involving visual scanning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes